(ISRG) Intuitive Surgical - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US46120E6023
Stock:
Total Rating 57
Risk 95
Buy Signal -0.04
| Risk 5d forecast | |
|---|---|
| Volatility | 32.0% |
| Relative Tail Risk | -10.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.44 |
| Alpha | -34.41 |
| Character TTM | |
|---|---|
| Beta | 1.167 |
| Beta Downside | 0.742 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.63% |
| CAGR/Max DD | 0.99 |
EPS (Earnings per Share)
Revenue
Description: ISRG Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 2.86b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 5.15 > 1.0 |
| NWC/Revenue: 77.23% < 20% (prev 64.24%; Δ 12.99% < -1%) |
| CFO/TA 0.15 > 3% & CFO 3.03b > Net Income 2.86b |
| Net Debt (-3.07b) to EBITDA (3.62b): -0.85 < 3 |
| Current Ratio: 4.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (360.4m) vs 12m ago -0.96% < -2% |
| Gross Margin: 66.00% > 18% (prev 0.67%; Δ 6532 % > 0.5%) |
| Asset Turnover: 51.00% > 50% (prev 44.34%; Δ 6.66% > 0%) |
| Interest Coverage Ratio: 32.58 > 6 (EBITDA TTM 3.62b / Interest Expense TTM 90.4m) |
Altman Z'' 7.34
| A: 0.38 (Total Current Assets 9.78b - Total Current Liabilities 2.01b) / Total Assets 20.63b |
| B: 0.34 (Retained Earnings 7.01b / Total Assets 20.63b) |
| C: 0.15 (EBIT TTM 2.95b / Avg Total Assets 19.73b) |
| D: 2.62 (Book Value of Equity 7.06b / Total Liabilities 2.69b) |
| Altman-Z'' Score: 7.34 = AAA |
Beneish M -3.03
| DSRI: 1.00 (Receivables 1.63b/1.36b, Revenue 10.06b/8.35b) |
| GMI: 1.02 (GM 66.00% / 67.46%) |
| AQI: 0.72 (AQ_t 0.27 / AQ_t-1 0.37) |
| SGI: 1.21 (Revenue 10.06b / 8.35b) |
| TATA: -0.01 (NI 2.86b - CFO 3.03b) / TA 20.63b) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of ISRG shares?
As of February 25, 2026, the stock is trading at USD 494.02 with a total of 1,401,152 shares traded.
Over the past week, the price has changed by +0.14%, over one month by -6.58%, over three months by -13.10% and over the past year by -16.41%.
Over the past week, the price has changed by +0.14%, over one month by -6.58%, over three months by -13.10% and over the past year by -16.41%.
Is ISRG a buy, sell or hold?
Intuitive Surgical has received a consensus analysts rating of 4.03.
Therefore, it is recommended to buy ISRG.
- StrongBuy: 14
- Buy: 8
- Hold: 10
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the ISRG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 611.8 | 23.8% |
| Analysts Target Price | 611.8 | 23.8% |
ISRG Fundamental Data Overview February 21, 2026
P/E Trailing = 63.3118
P/E Forward = 49.2611
P/S = 17.6258
P/B = 9.68
P/EG = 2.5335
Revenue TTM = 10.06b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 3.62b USD
Long Term Debt = 263.8m USD (estimated: total debt 302.8m - short term 39.0m)
Short Term Debt = 39.0m USD (from shortTermDebt, last quarter)
Debt = 302.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.07b USD (from netDebt column, last quarter)
Enterprise Value = 171.77b USD (177.40b + Debt 302.8m - CCE 5.93b)
Interest Coverage Ratio = 32.58 (Ebit TTM 2.95b / Interest Expense TTM 90.4m)
EV/FCF = 68.96x (Enterprise Value 171.77b / FCF TTM 2.49b)
FCF Yield = 1.45% (FCF TTM 2.49b / Enterprise Value 171.77b)
FCF Margin = 24.75% (FCF TTM 2.49b / Revenue TTM 10.06b)
Net Margin = 28.38% (Net Income TTM 2.86b / Revenue TTM 10.06b)
Gross Margin = 66.00% ((Revenue TTM 10.06b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 66.44% (prev 66.36%)
Tobins Q-Ratio = 8.33 (Enterprise Value 171.77b / Total Assets 20.63b)
Interest Expense / Debt = 29.85% (Interest Expense 90.4m / Debt 302.8m)
Taxrate = 16.34% (156.1m / 955.6m)
NOPAT = 2.46b (EBIT 2.95b * (1 - 16.34%))
Current Ratio = 4.87 (Total Current Assets 9.78b / Total Current Liabilities 2.01b)
Debt / Equity = 0.02 (Debt 302.8m / totalStockholderEquity, last quarter 17.82b)
Debt / EBITDA = -0.85 (Net Debt -3.07b / EBITDA 3.62b)
Debt / FCF = -1.23 (Net Debt -3.07b / FCF TTM 2.49b)
Total Stockholder Equity = 17.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.47% (Net Income 2.86b / Total Assets 20.63b)
RoE = 16.39% (Net Income TTM 2.86b / Total Stockholder Equity 17.43b)
RoCE = 16.65% (EBIT 2.95b / Capital Employed (Equity 17.43b + L.T.Debt 263.8m))
RoIC = 14.14% (NOPAT 2.46b / Invested Capital 17.43b)
WACC = 10.24% (E(177.40b)/V(177.70b) * Re(10.21%) + D(302.8m)/V(177.70b) * Rd(29.85%) * (1-Tc(0.16)))
Discount Rate = 10.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.31%
[DCF] Terminal Value 71.03% ; FCFF base≈2.02b ; Y1≈2.09b ; Y5≈2.39b
[DCF] Fair Price = 90.27 (EV 28.99b - Net Debt -3.07b = Equity 32.06b / Shares 355.1m; r=10.24% [WACC]; 5y FCF grow 4.02% → 2.90% )
EPS Correlation: 97.03 | EPS CAGR: 23.98% | SUE: 2.02 | # QB: 3
Revenue Correlation: 98.06 | Revenue CAGR: 19.11% | SUE: 2.17 | # QB: 6
EPS next Quarter (2026-03-31): EPS=2.12 | Chg7d=-0.000 | Chg30d=+0.001 | Revisions Net=+0 | Analysts=27
EPS current Year (2026-12-31): EPS=10.01 | Chg7d=-0.002 | Chg30d=+0.310 | Revisions Net=+24 | Growth EPS=+12.1% | Growth Revenue=+14.6%
EPS next Year (2027-12-31): EPS=11.43 | Chg7d=-0.002 | Chg30d=+0.257 | Revisions Net=+19 | Growth EPS=+14.2% | Growth Revenue=+13.6%
[Analyst] Revisions Ratio: +0.00 (10 Up / 10 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.6% (Discount Rate 10.2% - Earnings Yield 1.6%)
[Growth] Growth Spread = +7.8% (Analyst 16.4% - Implied 8.6%)
P/E Forward = 49.2611
P/S = 17.6258
P/B = 9.68
P/EG = 2.5335
Revenue TTM = 10.06b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 3.62b USD
Long Term Debt = 263.8m USD (estimated: total debt 302.8m - short term 39.0m)
Short Term Debt = 39.0m USD (from shortTermDebt, last quarter)
Debt = 302.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.07b USD (from netDebt column, last quarter)
Enterprise Value = 171.77b USD (177.40b + Debt 302.8m - CCE 5.93b)
Interest Coverage Ratio = 32.58 (Ebit TTM 2.95b / Interest Expense TTM 90.4m)
EV/FCF = 68.96x (Enterprise Value 171.77b / FCF TTM 2.49b)
FCF Yield = 1.45% (FCF TTM 2.49b / Enterprise Value 171.77b)
FCF Margin = 24.75% (FCF TTM 2.49b / Revenue TTM 10.06b)
Net Margin = 28.38% (Net Income TTM 2.86b / Revenue TTM 10.06b)
Gross Margin = 66.00% ((Revenue TTM 10.06b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 66.44% (prev 66.36%)
Tobins Q-Ratio = 8.33 (Enterprise Value 171.77b / Total Assets 20.63b)
Interest Expense / Debt = 29.85% (Interest Expense 90.4m / Debt 302.8m)
Taxrate = 16.34% (156.1m / 955.6m)
NOPAT = 2.46b (EBIT 2.95b * (1 - 16.34%))
Current Ratio = 4.87 (Total Current Assets 9.78b / Total Current Liabilities 2.01b)
Debt / Equity = 0.02 (Debt 302.8m / totalStockholderEquity, last quarter 17.82b)
Debt / EBITDA = -0.85 (Net Debt -3.07b / EBITDA 3.62b)
Debt / FCF = -1.23 (Net Debt -3.07b / FCF TTM 2.49b)
Total Stockholder Equity = 17.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.47% (Net Income 2.86b / Total Assets 20.63b)
RoE = 16.39% (Net Income TTM 2.86b / Total Stockholder Equity 17.43b)
RoCE = 16.65% (EBIT 2.95b / Capital Employed (Equity 17.43b + L.T.Debt 263.8m))
RoIC = 14.14% (NOPAT 2.46b / Invested Capital 17.43b)
WACC = 10.24% (E(177.40b)/V(177.70b) * Re(10.21%) + D(302.8m)/V(177.70b) * Rd(29.85%) * (1-Tc(0.16)))
Discount Rate = 10.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.31%
[DCF] Terminal Value 71.03% ; FCFF base≈2.02b ; Y1≈2.09b ; Y5≈2.39b
[DCF] Fair Price = 90.27 (EV 28.99b - Net Debt -3.07b = Equity 32.06b / Shares 355.1m; r=10.24% [WACC]; 5y FCF grow 4.02% → 2.90% )
EPS Correlation: 97.03 | EPS CAGR: 23.98% | SUE: 2.02 | # QB: 3
Revenue Correlation: 98.06 | Revenue CAGR: 19.11% | SUE: 2.17 | # QB: 6
EPS next Quarter (2026-03-31): EPS=2.12 | Chg7d=-0.000 | Chg30d=+0.001 | Revisions Net=+0 | Analysts=27
EPS current Year (2026-12-31): EPS=10.01 | Chg7d=-0.002 | Chg30d=+0.310 | Revisions Net=+24 | Growth EPS=+12.1% | Growth Revenue=+14.6%
EPS next Year (2027-12-31): EPS=11.43 | Chg7d=-0.002 | Chg30d=+0.257 | Revisions Net=+19 | Growth EPS=+14.2% | Growth Revenue=+13.6%
[Analyst] Revisions Ratio: +0.00 (10 Up / 10 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 8.6% (Discount Rate 10.2% - Earnings Yield 1.6%)
[Growth] Growth Spread = +7.8% (Analyst 16.4% - Implied 8.6%)